COR
Cencora, Inc.
NYSE · Healthcare · Medical - Distribution · US
$350.42
+2.91%Nov 4, 2026, 13:51 UTC
Cencora, Inc. reported quarterly earnings of $4.66 per share, up from $3.84 per share a year earlier and above the $4.56 consensus estimate.
Source:Nov 4, 2026, 11:35 UTC
Cencora reported fiscal 2026 fourth-quarter revenue of $88.4 billion, up 5.5%, and fiscal-year revenue of $337.4 billion, up 5.0%; fourth-quarter GAAP diluted EPS was $2.71 versus a loss of $1.75 per share a year earlier.
Source:Nov 4, 2026, 11:35 UTC
Cencora announced that it is realigning its corporate and reporting structure to strengthen execution and visibility.
Source:Oct 21, 2026, 15:30 UTC
Cencora, Inc. shares fell 4.84% to $325.50 within hours of the acquisition announcement.
Source:Oct 21, 2026, 11:30 UTC
Cencora announced that it signed a definitive agreement to acquire American Oncology Network.
Oct 2, 2026, 12:00 UTC
Cencora, Inc. announced it will release its fourth quarter fiscal 2026 results on November 4, 2026, before the New York Stock Exchange opens, and host a conference call the same day.
Source:Sep 25, 2026, 12:16 UTC
Cencora, Inc. appointed Robert E. Sanchez as a director effective October 1, 2026, granting him a pro-rated annual non-employee director equity award through the 2027 annual meeting.
Sep 4, 2026, 14:56 UTC
Cencora (COR) launched CGT Enablement, a service to help health systems build and scale cell and gene therapy programs with financial, operational, and access support.
Source:Sep 2, 2026, 12:30 UTC
Cencora, through its Accelerate Pharmacy Solutions, launched Cell and Gene Therapy Enablement, a service to help health systems evaluate, build, and scale cell and gene therapy programs.
Source:Aug 22, 2026, 07:10 UTC
Advisors Capital Management LLC disclosed a new minority stake in Cencora, Inc. by purchasing 2,644 shares valued at approximately $748,000, according to a Form 13F filing.
Source:Aug 14, 2026, 00:00 UTC
Lorence H. Kim, M.D. resigned from the Board of Directors of Cencora, Inc., effective August 13, 2026.
Aug 6, 2026, 11:05 UTC
Cencora repurchased $1 billion of its shares during the fiscal 2026 third quarter.
Source:Aug 5, 2026, 00:00 UTC
Cencora, Inc. amended its receivables securitization facility.
Aug 5, 2026, 00:00 UTC
Cencora, Inc. amended its multi-currency senior unsecured revolving credit facility, increasing aggregate commitments from $5.5 billion to $7.0 billion and extending maturity to July 2031.
Aug 5, 2026, 00:00 UTC
Cencora, Inc. reported Q3 2026 GAAP revenue of $84.8 billion, GAAP diluted EPS of $3.94, and adjusted diluted EPS of $4.48, with net income attributable to Cencora of $764 million.
Jul 20, 2026, 10:30 UTC
International Paper appointed Katherine Collins and Lori J Ryerkerk to its board, effective 1 October 2026.
Source:Jun 18, 2026, 15:36 UTC
Cencora launched an enhanced Nucleus solution for specialty practices, with a pilot underway across more than 20 physician practice sites.
Source:Jun 17, 2026, 12:00 UTC
Cencora launched a multi-site pilot of its enhanced Nucleus inventory management solution for specialty physician practices.
Source:Jun 15, 2026, 00:00 UTC
Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of Cencora, Inc., effective July 12, 2026.